As of 2026-03-25, the EV/EBITDA ratio of Cardiff Oncology Inc (CRDF) is -2.07. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Cardiff's latest enterprise value is 100.79 mil USD. Cardiff's TTM EBITDA according to its financial statements is -48.59 mil USD. Dividing these 2 quantities gives us the above Cardiff EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.9x - 16.5x | 14.0x |
| Forward P/E multiples | 17.6x - 21.3x | 19.7x |
| Fair Price | (12.25) - (11.44) | (11.72) |
| Upside | -808.4% - -761.5% | -777.5% |
| Date | EV/EBITDA |
| 2026-03-24 | -2.02 |
| 2026-03-23 | -2.14 |
| 2026-03-20 | -2.17 |
| 2026-03-19 | -2.20 |
| 2026-03-18 | -2.19 |
| 2026-03-17 | -2.34 |
| 2026-03-16 | -2.31 |
| 2026-03-13 | -2.26 |
| 2026-03-12 | -2.33 |
| 2026-03-11 | -2.47 |
| 2026-03-10 | -2.48 |
| 2026-03-09 | -2.44 |
| 2026-03-06 | -2.29 |
| 2026-03-05 | -2.27 |
| 2026-03-04 | -2.43 |
| 2026-03-03 | -2.30 |
| 2026-03-02 | -2.37 |
| 2026-02-27 | -2.37 |
| 2026-02-26 | -2.40 |
| 2026-02-25 | -2.33 |
| 2026-02-24 | -2.03 |
| 2026-02-23 | -1.84 |
| 2026-02-20 | -1.91 |
| 2026-02-19 | -1.93 |
| 2026-02-18 | -1.84 |
| 2026-02-17 | -1.84 |
| 2026-02-13 | -1.89 |
| 2026-02-12 | -1.86 |
| 2026-02-11 | -1.89 |
| 2026-02-10 | -1.82 |
| 2026-02-09 | -1.86 |
| 2026-02-06 | -1.89 |
| 2026-02-05 | -1.72 |
| 2026-02-04 | -1.86 |
| 2026-02-03 | -2.00 |
| 2026-02-02 | -2.05 |
| 2026-01-30 | -2.10 |
| 2026-01-29 | -1.91 |
| 2026-01-28 | -1.92 |
| 2026-01-27 | -2.45 |
| 2026-01-26 | -3.78 |
| 2026-01-23 | -3.72 |
| 2026-01-22 | -3.82 |
| 2026-01-21 | -3.71 |
| 2026-01-20 | -3.59 |
| 2026-01-16 | -3.69 |
| 2026-01-15 | -3.57 |
| 2026-01-14 | -3.59 |
| 2026-01-13 | -3.68 |
| 2026-01-12 | -3.68 |